July 5, 2018 10:40 AM EDT
News Briefing

FDA OKs Xeomin in fourth in­di­ca­tion; Nextbi­otix rais­es $8M for mi­cro­bio­me tech

Brittany Meiling

→ The FDA has green-light­ed Merz North Amer­i­ca’s sup­ple­men­tal Bi­o­log­ics Li­cense Ap­pli­ca­tion (sBLA) for Xeomin for the treat­ment of ex­ces­sive drool­ing (chron­ic sial­or­rhea) in adult …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times